Biologic therapy for Crohn's disease over the last 3 decades
Ji-Liang Shen1, Zheng Zhou2, Jia-Sheng Cao1
1Department of General Surgery, Sir Run-Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou 310016, Zhejiang Province, China.
Insights
This bibliometric analysis of biologic therapy for Crohn's disease (CD) identifies key research trends and influential contributions. It highlights anti-tumor necrosis factor biologics and monoclonal antibodies as leading topics, guiding future research and clinical practice.
Area of Science:
- Gastroenterology and Immunology
- Biologic Therapies
- Bibliometric Analysis
Background:
- Crohn's disease (CD) research is extensive, yet a comprehensive analysis of biologic therapy is lacking.
- Understanding the landscape of biologic therapy for CD is crucial for advancing patient care.
Purpose of the Study:
- To identify knowledge gaps in biologic therapy for Crohn's disease.
- To pinpoint areas of significant research interest and contribution in CD biologic therapy.
Main Methods:
- Bibliometric analysis of the top 100 highest-cited original articles on CD biologic therapy (1991-2020).
- Utilized Web of Science Core Collection for data extraction and analysis.
- Identified influential countries, institutions, authors, and publications.
Main Results:
- The 2000s saw the most significant growth in influential publications.
- The United States and Belgium led in publications, with key institutions including University Hospital Gasthuisberg and the University of Chicago.
- Rutgeerts P, Sandborn WJ, and Feagan BG were the most prolific authors. Anti-tumor necrosis factor biologics and monoclonal antibodies were the most studied topics.
Conclusions:
- Bibliometric analysis reveals key contributions shaping the field of biologic therapy for CD.
- Findings provide valuable insights for clinicians and researchers in Crohn's disease management.
- Identifies anti-TNF biologics and monoclonal antibodies as focal points for future research.
Background:
Despite the overload of publications on Crohn's disease (CD), no comprehensive analysis of biologic therapy for CD has been reported.
Aim:
To determine knowledge gaps and identify areas of interest of biologic therapy for CD.
Methods:
The top 100 highest-cited original articles were identified from January 1991 to December 2020 in the Clarivate Analytics Web of Science Core Collection database. We conducted a bibliometric analysis of biologic therapy for CD based on total citations, summarized the bibliographic information of the articles related to CD biologic therapy, and explored the research hotspots.
Results:
The top 100 highest-cited original articles were identified with total citations ranging from 307 to 2978. The 2000s (Period II, n = 66) yielded the most influential original articles and saw the most dramatic growth. Among the top 10 countries, including 8 European countries and 2 North American countries, the United States (n = 37) and Belgium (n = 20) contributed the most publications. Among the top 10 institutions, the University Hospital Gasthuisberg in Belgium (n = 23), the University of Chicago in the United States (n = 20), and the Mayo Clinic in the United States (n = 17) published the most papers. Regarding authors, Rutgeerts P in Belgium (n = 32), Sandborn WJ in the United States (n = 23), and Feagan BG in Canada (n = 18) published the highest number of studies. The cooperation relationships between the United States and Europe were most frequent. Gastroenterology (impact factor = 22.682) published the most articles on biologic therapy for CD (n = 32) with 17654 total citations. Anti-tumor necrosis factor biologics and monoclonal antibodies were the most studied topics.
Conclusion:
The bibliometric analysis emphasized the key contributions to the development of the specialized field. These data would provide useful research insights into biologic therapy for CD for clinicians and researchers.
More Related Videos
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
01:29Drugs for Treatment of Ulcerative Colitis in IBD
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...